Hongen Lei,1Jing Liu,1Huixi Li,1Lin Wang,1Yongde Xu,1Wenjie Tian,2Guiting Lin,3 and Zhongcheng Xin1Author informationArticle notesCopyright and License informationDisclaimer


Although phosphodiesterase type 5 inhibitors (PDE5Is) are a revolution in the treatment of erectile dysfunction (ED) and have been marketed since 1998, they cannot restore pathological changes in the penis. Low-energy shock wave therapy (LESWT) has been developed for treating ED, and clinical studies have shown that LESWT has the potential to affect PDE5I non-responders with ED with few adverse effects. Animal studies have shown that LESWT significantly improves penile hemodynamics and restores pathological changes in the penis of diabetic ED animal models. Although the mechanisms remain to be investigated, recent studies have reported that LESWT could partially restore corpus cavernosum fibromuscular pathological changes, endothelial dysfunction, and peripheral neuropathy. LESWT could be a novel modality for treating ED, and particularly PDE5I non-responders with organic ED, in the near future. However, further extensive evidence-based basic and clinical studies are needed. This review intends to summarize the scientific background underlying the effect of LESWT on ED.

Keywords: Erectile dysfunction, ESWL, Extracorporeal shockwave lithotripsy, Phosphodiesterase 5 inhibitors

Link to download the full article: 10.5534/wjmh.2013.31.3.208